期刊文献+

替吉奥胶囊联合奥沙利铂治疗老年胃癌疗效观察 被引量:5

原文传递
导出
摘要 目的 观察替吉奥胶囊(S1)联合奥沙利铂(L-OHP)治疗老年胃癌的近期疗效.方法 将52例老年晚期胃癌患者随机分为两组,治疗组(L-OHP+ S-1方案)25例,替吉奥胶囊70mg/(m2 ·d),分2次早晚饭后口服,第1~ 14天;奥沙利铂130 mg/m2,静脉滴注,第1天.对照组(L-OHP+ 5-FU)27例,CF 0.2 g/(m2.d),静脉滴注2h,第1~2天,5-氨尿嘧啶(5-FU) 400 mg/(m2.d)静脉滴注,第1~2天,5-FU 600 mg/(m2.d),持续静脉滴注,44h;奥沙利铂130 mg/m2,静脉滴注,第1天.3周为1个周期.每例患者至少进行2个周期的治疗,治疗结束后1个月评价近期疗效.结果 两组患者的有效率(CR+ PR)分别为56.0%和44.4%,疾病控制率(DCR)为84.0%和74.1%,中位疾病进展时间为6.4个月和6.2个月,1年生存率分别为52.3%和42.2%.结论 替吉奥联合奥沙利铂方案治疗老年晚期胃癌的近期疗效较好,不良反应可以耐受,值得进一步研究应用.
出处 《中国实用医刊》 2013年第21期84-85,共2页 Chinese Journal of Practical Medicine
  • 相关文献

参考文献5

  • 1孙燕,石远凯.临床肿瘤内科手册[M].5版.北京:人民卫生出版社,2009.
  • 2Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combi- nation of irinotecan plus cisplatin versus S-1 in metastatic gastric canc- er: a randomised phase 3 study [ J ]. Lancet Oncol, 2009, 10 ( 11 ) : 1063-1069.
  • 3张星霖,贾伟丽.替吉奥胶囊治疗老年晚期胃癌的临床观察[J].现代肿瘤医学,2011,19(6):1189-1190. 被引量:44
  • 4De Vita F, Orditura M, Matano E, et al. A phase II study of bi weekly oxaliplat in plus in fusional 5-fluorouracil and folinicacid(FOLFOX-4) as first-line treatment of advanced gastric cancer patients [ J ]. Br J Cancer, 2005,92 ( 9 ) : 1644.
  • 5黄镜,王向玲,周一,周爱萍,陶云霞,王金万.替吉奥为基础的化疗在消化道肿瘤中安全性的观察和分析[J].癌症进展,2011,9(6):707-710. 被引量:32

二级参考文献20

  • 1Wesolowski R, Lee C, Kim R. Is there a role for second - line chemotherapy in adavanced gastric cancer [ J ] ? Lancet Oncol, 2009,10:903 - 912.
  • 2Maehara Y. S - 1 in gastric cancer: a comprehensive review [ J]. Gastric Cancer,2003,6 ( Suppl 1 ) :2 - 8.
  • 3M Jin, H Lu, J Li, et al. Ramdomized 3 - armed phase Ⅲ study of S - 1 monotherapy versus S - 1/CDDP(SP) versus 5 - FU/CDDP (FP) in paitents(pts) with advanced gastric cancer( AGC ) : SC - 101 study[J]. J Clin Oneol,26(suppl):4533.
  • 4N Boku, S Yamamoto, K Shirao, et al. Randomized phase Ⅲ study of 5 -fluorouracil (5 - FU) alone versus combination of irinotecan and cisplatin(CP) versus S- 1 alone in advanced gastric cancer (JCOG9912) [J]. J Clin Ocol,2007,25:18.
  • 5Koizumi W, Tanabe S, Saigenji K, et al. GotohM : Phase Ⅰ / Ⅱ study of S1 combined with cisplatin in patients with advanced gastric cancer[ J]. Br Cancer,2003,89:2207.
  • 6Wasaburo K, Hiroyuki N, Takuo H, et al. S1 plus cisplatin versus S1 alone for first - line treatment of advanced gastric cancer( SPIR- ITS trial) :a phase Ⅲ trial [J]. Lancet 0ncol,2008,9(3) :215 - 221.
  • 7Ajani J A,Rodriguez W,Bodoky G,et al.Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study:the FLAGS trial[J].J Clin Oncol,2010,28 (9):1547-1553.
  • 8Koizumi W,Tanabe S,Saigenji K,et al.PhaseⅠ/Ⅱ study of S-1 combined with cisplatin in patients with advanced gastric cancer[J].Br J Cancer,2003,89 (12):2207-2212.
  • 9Shirasaka T,Shimamoto Y,Ohshimo H,et al.Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators[J].Anticancer Drugs,1996,7 (5):548-557.
  • 10Diasio R B.Clinical implications of dihydropyrimidine dehydrogenase inhibition[J].Oncoloy (Williston Park),1999,13 (Suppl 3):17-21.

共引文献118

同被引文献49

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部